Literature DB >> 17573977

Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns.

Ignacio Ferreira-González1, Gaietà Permanyer-Miralda, Jason W Busse, Dianne M Bryant, Victor M Montori, Pablo Alonso-Coello, Stephen D Walter, Gordon H Guyatt.   

Abstract

OBJECTIVE: To investigate the rationale, potential problems and solutions of using composite endpoints (CEPs) for the assessment of intervention effects. STUDY DESIGN AND
SETTING: This study is a systematic review. We searched MEDLINE, EMBASE, and the Science Citation Index, for publications appearing between 1980 and September 2005, and reviewed potentially informative textbooks. Eligible articles provided a commentary, analysis, or discussion of CEPs for any of the following areas: (1) rationale, (2) interpretation or meaning, (3) advantages, (4) limitations or conceptual problems, and (5) recommendations for use.
RESULTS: Seventeen articles and one textbook proved eligible. Decreases in sample size requirements and ability to assess the net effect of an intervention were the most commonly cited advantages. Authors noted the risk of misinterpretation when heterogeneity among components with respect to either patient importance or magnitude of treatment effects as the most salient disadvantage. There were discrepancies between authors concerning the usefulness of CEPs to avoid bias from competing risks and when the direction of the effect of therapy differs across components.
CONCLUSION: Methodologists have given limited attention to CEPs and their views are sometimes contradictory. Further work is needed to establish the role of CEPs in research and in guiding clinical practice.

Entities:  

Mesh:

Year:  2007        PMID: 17573977     DOI: 10.1016/j.jclinepi.2006.10.020

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  45 in total

1.  Peritoneal dialysis patients with critical illness: insurance may be hard to come by.

Authors:  K Scott Brimble; Michael Walsh
Journal:  Perit Dial Int       Date:  2012 Jan-Feb       Impact factor: 1.756

2.  Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Gordon H Guyatt; Susan L Norris; Sam Schulman; Jack Hirsh; Mark H Eckman; Elie A Akl; Mark Crowther; Per Olav Vandvik; John W Eikelboom; Marian S McDonagh; Sandra Zelman Lewis; David D Gutterman; Deborah J Cook; Holger J Schünemann
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Identifying outcomes of clinical genetic services: qualitative evidence and methodological considerations.

Authors:  Christalla Pithara
Journal:  J Genet Couns       Date:  2013-09-14       Impact factor: 2.537

4.  Clinical Trials Targeting Aging and Age-Related Multimorbidity.

Authors:  Mark A Espeland; Eileen M Crimmins; Brandon R Grossardt; Jill P Crandall; Jonathan A L Gelfond; Tamara B Harris; Stephen B Kritchevsky; JoAnn E Manson; Jennifer G Robinson; Walter A Rocca; Marinella Temprosa; Fridtjof Thomas; Robert Wallace; Nir Barzilai
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2017-03-01       Impact factor: 6.053

5.  Association of Skin Psoriasis and Somatic Comorbidity With the Development of Psychiatric Illness in a Nationwide Swedish Study.

Authors:  Kirk Geale; Martin Henriksson; Jussi Jokinen; Marcus Schmitt-Egenolf
Journal:  JAMA Dermatol       Date:  2020-07-01       Impact factor: 10.282

6.  An optimal Wilcoxon-Mann-Whitney test of mortality and a continuous outcome.

Authors:  Roland A Matsouaka; Aneesh B Singhal; Rebecca A Betensky
Journal:  Stat Methods Med Res       Date:  2016-12-29       Impact factor: 3.021

7.  When novelty is not enough.

Authors:  Michael F Murphy
Journal:  Am Health Drug Benefits       Date:  2008-03

8.  Role and rationale for the use of milnacipran in the management of fibromyalgia.

Authors:  Jay D Kranzler; R Michael Gendreau
Journal:  Neuropsychiatr Dis Treat       Date:  2010-05-25       Impact factor: 2.570

Review 9.  Development of a composite endpoint for randomized controlled trials in pancreaticoduodenectomy.

Authors:  Marielle M E Coolsen; Stefan H E M Clermonts; Ronald M van Dam; Bjorn Winkens; Massimo Malagó; Giuseppe K Fusai; Cornelis H C Dejong; Steven W M Olde Damink
Journal:  World J Surg       Date:  2014-06       Impact factor: 3.352

10.  Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials.

Authors:  Roger Chou; Susan Carson; Benjamin K S Chan
Journal:  J Gen Intern Med       Date:  2008-12-17       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.